72. Pituitary ADH secretion disorder
36 clinical trials,   22 drugs   (DrugBank: 5 drugs),   2 drug target genes,   4 drug target pathways

Searched query = "Pituitary ADH secretion disorder", "Inappropriate antidiuretic hormone secretion", "Syndrome of inappropriate secretion of antidiuretic hormone", "Inappropriate ADH syndrome", "Syndrome of inappropriate ADH", "Central diabetes insipidus", "Syndrome of inappropriate secretion of ADH", "SIADH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04447911
(ClinicalTrials.gov)
January 202110/6/2020Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic HyponatremiaEffects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia - a Monocentric Randomized Double-blind Placebo-controlled Trial (the EMPOWER Study)Hyponatremia;SIADH;Liver Failure;Kidney FailureDrug: Empagliflozin 25 MG;Drug: PlaceboUniversity Hospital, Basel, SwitzerlandNULLNot yet recruiting18 YearsN/AAll172Phase 4NULL
2NCT03202667
(ClinicalTrials.gov)
December 15, 201727/6/2017Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx StudyEffects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx StudySIAD - Syndrome of Inappropriate Antidiuresis;HyponatremiaDrug: Empagliflozin 25mg;Drug: PlaceboUniversity Hospital, Basel, SwitzerlandNULLRecruiting18 YearsN/AAll16Phase 2;Phase 3Switzerland
3NCT02874807
(ClinicalTrials.gov)
September 5, 201617/8/2016Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND StudyEffects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND StudySIADHDrug: Empagliflozin;Other: PlaceboUniversity Hospital, Basel, SwitzerlandNULLCompleted18 Years84 YearsAll88Phase 2;Phase 3Switzerland
4NCT02729766
(ClinicalTrials.gov)
March 201624/3/2016Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE StudyEffects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE StudyInappropriate ADH SyndromeOther: Induced hypotonic hyponatremia - SIAD model;Drug: Empagliflozin 25mg Tbl;Drug: Placebo P-TabletUniversity Hospital, Basel, SwitzerlandNULLCompleted18 Years65 YearsBoth15Phase 2;Phase 3Switzerland